Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lonza Won’t Compete With Partners In Teva Biosimilars Collaboration

This article was originally published in The Pink Sheet Daily

Executive Summary

Swiss firm sees potential to earn $500 million to $750 million annually in follow-on biologics market.

You may also be interested in...



Teva Adds To Biosimilars Capabilities Through Partnership With Lonza

Israeli generic giant, Swiss CMO announce joint venture to co-develop, manufacture and market biosimilars.

Merck Announces Major FOB Initiative With Its New Business Unit

Merck BioVentures plans to launch follow-on version of Amgen’s Aranesp by 2012.

Medarex/BMS Working To Shift Ipilimumab Trial Endpoint

Overall survival is more valid than freedom from progression in Phase III melanoma trial, firm says.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068533

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel